What was known before {#section23-2054358120940433}
=====================

The 3 most common interventions used to manage stones are shock wave lithotripsy, ureteroscopy, and percutaneous nephrolithotomy. These interventions may have differential efficacy and safety profiles when used in patients with autosomal dominant polycystic kidney disease (ADPKD) compared with the general population.

What this adds {#section24-2054358120940433}
==============

This systematic review of 25 studies (311 patients in total) demonstrated estimates on the proportion of patients with autosomal dominant polycystic kidney disease (ADKPD) who were stone free after an intervention vary widely in the literature, as well as the proportion who experienced at least one postoperative complication. Many studies had methodological limitations. The results of this review confirm more rigorous studies are needed.

Introduction {#section25-2054358120940433}
============

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic kidney disorder with no cure.^[@bibr1-2054358120940433],[@bibr2-2054358120940433]^ It is characterized by focal cyst development leading to a progressive enlargement of both kidneys and kidney failure.^[@bibr3-2054358120940433],[@bibr4-2054358120940433]^ The prevalence of stones in patients with ADPKD ranges from 3% to 59%.[@bibr5-2054358120940433] The wide range of kidney stone prevalence reported in the literature can be explained by several factors including inconsistent stone definitions, different distributions of stone risk factors, potential recall bias in studies that relied on patient self-reported data to identify stone events, and relying on past imaging reports for reasons other than stone identification.^[@bibr5-2054358120940433]^ Kidney stones in patients with ADPKD are associated with significant morbidity. For example, stones are a major determinant of pain and may accelerate chronic kidney disease progression.^[@bibr6-2054358120940433],[@bibr7-2054358120940433]^ For these reasons, effective stone management is important in patients with ADPKD. However, the distorted kidneys and the reduced kidney function in patients with ADPKD may make active stone removal more challenging. For example, the cysts in patients with ADPKD may hinder optimal stone access and hence the success rate of stone interventions.

A published clinical practice guideline states that stone management in patients with ADPKD should not differ from the general population, and recommends that if necessary that stone interventions be considered.^[@bibr8-2054358120940433]^ The guideline authors also indicated that their recommendation was based on limited evidence.

Irrespective of whether a patient has ADPKD or not, urgent intervention is often required in the presence of infection/urosepsis, intractable pain, vomiting, impending acute renal failure, and/or obstruction.^[@bibr9-2054358120940433]^ Currently, shock wave lithotripsy (SWL), ureteroscopy, and percutaneous nephrolithotomy (PCNL) are commonly used procedures to remove stones.^[@bibr8-2054358120940433]^ The choice of stone intervention to treat stone is primarily dependent on stone characteristics such as stone location and size and availability of equipment. In some instances, a combination of interventions may be required to remove stones. Shock wave lithotripsy emits shock waves from an external device, which then propagate through the body and cause the stones to fragment.^[@bibr10-2054358120940433],[@bibr11-2054358120940433]^ The fragmented stones then pass on their own in the subsequent weeks. Shock wave lithotripsy is least invasive stone intervention and is not recommended for pregnant women, and for patients with uncontrolled hypertension, uncontrolled coagulopathy, or a distal urinary obstruction to where stone is located.^[@bibr12-2054358120940433]^ Ureteroscopy is performed by inserting a rigid, semi-rigid, or flexible ureteroscope through the urethra and into the ureter and positioning it close to the stone.^[@bibr13-2054358120940433],[@bibr14-2054358120940433]^ Instruments, such as laser, are used to fragment the stones, and these stone fragments can be left to pass or can be removed using instruments such as stone baskets or graspers.^[@bibr15-2054358120940433]^ During PCNL, a renal calyx is punctured percutaneously with fluoroscopy and/or ultrasound guidance to gain an access to the stone.^[@bibr16-2054358120940433]^ Stones are then fragmented using instruments, such as lasers or pneumatic lithotripters, and removed using tools such as graspers or suction devices.^[@bibr9-2054358120940433]^ Percutaneous nephrolithotomy is relatively the most invasive stone intervention.^[@bibr9-2054358120940433]^

We undertook this systematic review to critically appraise and summarize the results of studies which described the efficacy and safety outcomes of the 3 main stone interventions (SWL, ureteroscopy, and PCNL) in adults with ADPKD. The outcomes of interest were the proportion of patients who were stone free after the intervention and the proportion who experienced at least one postoperative complication.

Methods {#section26-2054358120940433}
=======

Design and Study Selection {#section27-2054358120940433}
--------------------------

We conducted this systematic review using an internal prespecified protocol and reported this review according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement ([Supplementary Table S1](https://journals.sagepub.com/doi/suppl/10.1177/2054358120940433)).^[@bibr17-2054358120940433]^

We included studies that met the following eligibility criteria: (1) published English language full-text articles and conference proceedings; (2) any study design; (3) at least 2 patients with ADPKD included in the study, (4) with and without a comparator group, and (5) described any efficacy or safety outcome following at least any one of SWL, ureteroscopy, and/or PCNL in adults with ADPKD and kidney stones. If multiple publications reported outcomes on similar group of patients, then we abstracted data on the study published more recently. We only included studies with comparators if outcomes of a stone intervention were compared between ADPKD and non-ADPKD populations who underwent the same stone intervention; we did not include studies if outcomes of 2 different interventions were compared in patients with ADPKD.

Identifying Relevant Articles {#section28-2054358120940433}
-----------------------------

With an experienced librarian, we developed a comprehensive search strategy ([Supplementary Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2054358120940433)) to identify eligible published, original journal articles and conference proceedings on kidney stone interventions performed in adults with ADPKD. We retrieved all citations using MEDLINE (1947 to February 2019), EMBASE (1947 to February 2019), Web of Science, BIOSIS Preview (1955 to February 2019), and CINAHL.

Two reviewers (V.K. and R.J.) removed duplicates and rated the remaining title and abstracts obtained from the search syntax. We retrieved the full text of all "relevant" and "potentially relevant" articles to further assess study eligibility. To identify additional eligible articles, we also manually searched the reference list of all included articles, used the "cited by" function in Google Scholar and Web of Science, and the "similar article" feature of PubMed. The 2 reviewers resolved any disagreement by consensus.

Data Abstraction {#section29-2054358120940433}
----------------

One author (V.K.) developed a standardized form to abstract data from each study including information on study, patient and stone characteristics, interventions, and outcomes. Two authors (V.K. and R.J.) pilot-tested and improved the form by independently extracting data from 5 eligible articles. Using the final data abstraction form (see [Supplementary Table S3](https://journals.sagepub.com/doi/suppl/10.1177/2054358120940433)), 2 abstractors independently extracted data from remaining studies, recorded the data, and resolved any disagreement by consensus.

Two authors (V.K. and G.G.) assessed the methodological quality of each of the included studies using a modified Downs and Black checklist ([Supplementary Table S4](https://journals.sagepub.com/doi/suppl/10.1177/2054358120940433)). We assigned a score between 0 and 22 for all included studies, with a higher score indicating better methodological quality.

Data Analysis {#section30-2054358120940433}
-------------

Results were described qualitatively. The heterogeneity of included studies precluded a formal meta-analysis.

Results {#section31-2054358120940433}
=======

[Figure 1](#fig1-2054358120940433){ref-type="fig"} summarizes the study selection process. Our search strategy yielded 221 citations that we reviewed and identified 24 eligible articles. We identified an additional article when manually searching the reference lists of the study conducted by Delakas et al.^[@bibr18-2054358120940433]^ This yielded a total of 25 relevant articles (311 patients with ADPKD) published between 1993 and 2019. Most studies were conducted in India (n = 7) followed by the United States (n = 6), China (n = 3), Greece (n = 2), and Kuwait (n = 2). One study was conducted in each of the following countries: Azerbaijan, Denmark, Iran, Romania, and Taiwan. Of the 25 included articles, 24 studies were case series (96%), and 1 (4%) was a cohort study. Sixteen (64%) of these were full-text journal articles, and 9 (36%) were conference proceedings.

![Study selection.](10.1177_2054358120940433-fig1){#fig1-2054358120940433}

The number of patients in each study ranged from 2 to 29 cases (2-30 kidneys), and the mean age of the patients ranged from 32 to 61 years. The stone interventions were performed between October 1981 and January 2017. It was unclear whether the interventions were emergent or elective in all included studies. The study and patient characteristics of each included study are summarized in [Table 1](#table1-2054358120940433){ref-type="table"}, and overall outcomes of stone interventions are listed in [Table 2](#table2-2054358120940433){ref-type="table"}.

###### 

Study and Patient Characteristics of Included Studies.

![](10.1177_2054358120940433-table1)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, (y)\                                                                         No. of cases (no. of kidneys)   No. of centers   Recruitment period              Length of follow-up, mean (SD)                                 Mean age (SD), y   No. of male (%)   Quality score^[a](#table-fn2-2054358120940433){ref-type="table-fn"}^
  *Country* (citation)                                                                                                                                                                                                                                                      
  ------------------------------------------------------------------------------------ ------------------------------- ---------------- ------------------------------- -------------------------------------------------------------- ------------------ ----------------- ----------------------------------------------------------------------
  *Shock Wave Lithotripsy---Case Series*                                                                                                                                                                                                                                    

   Baishya et al (2012)^[b](#table-fn3-2054358120940433){ref-type="table-fn"}^\        3 (3)                           Unclear          Since 1992                      1.5 (1.3) y                                                    NR                 NR                9
  *India* (^[@bibr14-2054358120940433]^)                                                                                                                                                                                                                                    

   Cass (1995)^[b](#table-fn3-2054358120940433){ref-type="table-fn"}^\                 4 (NR)                          1                NR                              3 mo^[c](#table-fn4-2054358120940433){ref-type="table-fn"}^    61 (12)            2 (50)            7
  *United States* (^[@bibr19-2054358120940433]^)                                                                                                                                                                                                                            

   Chen et al (1993)^[b](#table-fn3-2054358120940433){ref-type="table-fn"}^\           2 (2)                           1                June 1986 to December 1989      NR                                                             NR                 NR                9
  *Taiwan* (^[@bibr20-2054358120940433]^)                                                                                                                                                                                                                                   

   Delakas et al (1997)\                                                               13 (16)                         1                April 1990 to October 1994      5.6 (NR) mo                                                    55 (NR)            7 (54)            9
  *Greece* (^[@bibr18-2054358120940433]^)                                                                                                                                                                                                                                   

   Deliveliotis et al (2002)^[b](#table-fn3-2054358120940433){ref-type="table-fn"}^\   4 (Unclear)                     Unclear          NR                              1 mo^[c](#table-fn4-2054358120940433){ref-type="table-fn"}^    49 (NR)            3 (75)            8
  *Greece* (^[@bibr21-2054358120940433]^)                                                                                                                                                                                                                                   

   Ng et al (2000)^[b](#table-fn3-2054358120940433){ref-type="table-fn"}^\             3 (3)                           1                Since 1993                      NR                                                             NR                 NR                9
  *United States* (^[@bibr22-2054358120940433]^)                                                                                                                                                                                                                            

   Singh et al (2019)^[b](#table-fn3-2054358120940433){ref-type="table-fn"}^\          3 (3)                           1                January 1990 to July 2014       NR                                                             NR                 NR                12
  *India* (^[@bibr23-2054358120940433]^)                                                                                                                                                                                                                                    

  *Ureteroscopy---Case Series*                                                                                                                                                                                                                                              

   Baishya et al (2012)^[b](#table-fn3-2054358120940433){ref-type="table-fn"}^\        2 (3)                           Unclear          Since 1992                      7.3 (1.2) mo                                                   NR                 NR                9
  *India* (^[@bibr14-2054358120940433]^)                                                                                                                                                                                                                                    

   Franke et al (2011)^[b](#table-fn3-2054358120940433){ref-type="table-fn"}^\         9 (NR)                          1                NR                              NR                                                             NR                 NR                7
  *Denmark* (^[@bibr24-2054358120940433]^)                                                                                                                                                                                                                                  

   Geavlete et al (2017)^[b](#table-fn3-2054358120940433){ref-type="table-fn"}^\       11 (Unclear)                    1                January 2007 to January 2017    NR                                                             61 (NR)            NR                8
  *Romania* (^[@bibr25-2054358120940433]^)                                                                                                                                                                                                                                  

   Ng et al (2000)^[b](#table-fn3-2054358120940433){ref-type="table-fn"}^\             2 (3)                           1                Since 1993                      NR                                                             NR                 NR                9
  *United States* (^[@bibr22-2054358120940433]^)                                                                                                                                                                                                                            

   Singh et al (2019)^[b](#table-fn3-2054358120940433){ref-type="table-fn"}^\          5 (6)                           1                January 1990 to July 2014       NR                                                             NR                 NR                12
  *India* (^[@bibr23-2054358120940433]^)                                                                                                                                                                                                                                    

   Yili et al (2012)\                                                                  13 (15)                         1                2005 to 2010                    3 (NR) y                                                       35 (NR)            9 (69)            11
  *China* (^[@bibr13-2054358120940433]^)                                                                                                                                                                                                                                    

  *Percutaneous Nephrolithotomy---Cohort*                                                                                                                                                                                                                                   

   Khorrami et al (2012)\                                                              ADPKD: 8 (NR)\                  1                2003 to 2011                    NR                                                             ADPKD: 45 (5)\     ADPKD: 7 (88)\    4
  *Iran* (^[@bibr26-2054358120940433]^)                                                CONTROL: 100 (NR)                                                                                                                               CONTROL: 47 (4)    CONTROL: NR       

  *Percutaneous Nephrolithotomy---Case Series*                                                                                                                                                                                                                              

   Al-Kandari et al (2009)\                                                            19 (20)                         2                1995 to 2007                    NR                                                             42 (9)             12 (63)           11
  *Kuwait* (^[@bibr27-2054358120940433]^)                                                                                                                                                                                                                                   

   Al-Kandari et al (2008)\                                                            29 (30)                         2                NR                              NR                                                             NR                 21 (72)           4
  *United States* (^[@bibr28-2054358120940433]^)                                                                                                                                                                                                                            

   Baishya et al (2012)^[b](#table-fn3-2054358120940433){ref-type="table-fn"}^\        3 (3)                           Unclear          Since 1992                      2.2 (0.8) y                                                    NR                 NR                9

  *India* (^[@bibr14-2054358120940433]^)                                                                                                                                                                                                                                    

   Bendigeri et al (2016)\                                                             13 (17)                         NR               NR                              NR                                                             NR                 10 (77)           8
  *India* (^[@bibr29-2054358120940433]^)                                                                                                                                                                                                                                    

   Boaz et al (2016)\                                                                  19 (23)                         Unclear          January 2003 to July 2015       NR                                                             NR                 NR                6
  *India* (^[@bibr30-2054358120940433]^)                                                                                                                                                                                                                                    

   Enganti et al (2017)\                                                               22 (Unclear)                    Unclear          January 2014 to April 2016      NR                                                             42 (NR)            NR                4
  *India* (^[@bibr31-2054358120940433]^)                                                                                                                                                                                                                                    

   Ismayil et al (2014)^[b](#table-fn3-2054358120940433){ref-type="table-fn"}^\        3 (NR)                          NR               2004 to 2014                    NR                                                             NR                 NR                6
  *Azerbaijan* (^[@bibr32-2054358120940433]^)                                                                                                                                                                                                                               

   Khadgi et al (2016)\                                                                7 (NR)                          NR               March 2010 to September 2012    NR                                                             42 (8)             3 (43)            12
  *Kuwait* (^[@bibr33-2054358120940433]^)                                                                                                                                                                                                                                   

   Lei et al (2014)\                                                                   23 (23)                         Unclear          January 2007 to December 2012   NR                                                             43 (11)            17 (74)           12
  *China* (^[@bibr34-2054358120940433]^)                                                                                                                                                                                                                                    

   Sabnis et al (2016)\                                                                10 (NR)                         NR               NR                              NR                                                             NR                 8 (80)            7

  *United States* (^[@bibr35-2054358120940433]^)                                                                                                                                                                                                                            

   Singh et al (2013)\                                                                 22 (26)                         1                2002 to 2011                    35 (NR) mo                                                     38 (NR)            NR                8
  *India* (^[@bibr36-2054358120940433]^)                                                                                                                                                                                                                                    

   Singh et al (2019)^[b](#table-fn3-2054358120940433){ref-type="table-fn"}^\          6 (6)                           1                January 1990 to July 2014       NR                                                             NR                 NR                12
  *India* (^[@bibr23-2054358120940433]^)                                                                                                                                                                                                                                    

   Srivastava et al (2012)\                                                            22 (25)                         1                January 2000 to January 2010    NR                                                             40 (14)            18 (82)           10
  *India* (^[@bibr37-2054358120940433]^)                                                                                                                                                                                                                                    

   Umbreit et al (2010)\                                                               9 (11)                          1                October 1981 to February 2009   2.7 (NR) y                                                     32 (NR)            7 (78)            9
  *United States* (^[@bibr38-2054358120940433]^)                                                                                                                                                                                                                            

   Wang et al (2017)\                                                                  11 (13)                         Unclear          Since 2010                      NR                                                             50 (13)            8 (73)            7
  *United States* (^[@bibr39-2054358120940433]^)                                                                                                                                                                                                                            

   Zhang et al (2014)\                                                                 11 (12)                         1                January 2002 to December 2012   36 mo^[c](#table-fn4-2054358120940433){ref-type="table-fn"}^   42 (11)            7 (64)            11
  *China* (^[@bibr40-2054358120940433]^)                                                                                                                                                                                                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* NR = not reported; ADPKD = autosomal dominant polycystic kidney disease; SD = standard deviation.

A modified Downs and Black checklist was used to assess the methodological quality of each included study. The methods quality score ranged between 0 and 22 with higher scores indicating higher quality.

The described cases are a subset of a larger case series.

The reported length of follow-up is not the average but rather constant for all included patients.

###### 

Outcomes of Stone Interventions.

![](10.1177_2054358120940433-table2)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (y)Country (citation)                              No. of patients stone free after 1 session (%)   No. of patients who underwent follow-up procedures (%)   Intraoperative complications, no. of patients (%)                                            Postoperative complications, no. of patients (%)                                                                        Preoperative serum creatinine (mean \[SD; range\]), µmol/L   Postoperative serum creatinine (mean \[SD; range\]), µmol/L
  --------------------------------------------------------- ------------------------------------------------ -------------------------------------------------------- -------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------------
  *Shock Wave Lithotripsy---Case Series*                                                                                                                                                                                                                                                                                                                                                                                                                

   Baishya et al^[@bibr14-2054358120940433]^ (2012)\        0 (0)                                            2 (67)                                                   NR                                                                                           NR                                                                                                                      NR                                                           NR
  *India*                                                                                                                                                                                                                                                                                                                                                                                                                                               

   Cass^[@bibr19-2054358120940433]^ (1995)\                 2 (50)                                           Unclear                                                  NR                                                                                           None                                                                                                                    NR                                                           NR
  *United States*                                                                                                                                                                                                                                                                                                                                                                                                                                       

   Chen et al^[@bibr20-2054358120940433]^ (1993)\           0 (0)                                            NR                                                       NR                                                                                           None                                                                                                                    NR                                                           NR
  *Taiwan*                                                                                                                                                                                                                                                                                                                                                                                                                                              

   Delakas et al^[@bibr18-2054358120940433]^ (1997)\        9 (69)                                           2 (15)                                                   None                                                                                         • At least one complication: Unclear\                                                                                   NR                                                           NR
  *Greece*                                                                                                                                                                                                                                                         • Colic pain that improved with oral analgesics: 3 (23)\                                                                                                                             
                                                                                                                                                                                                                                                                   • Transient gross hematuria: 8 (62)                                                                                                                                                  

   Deliveliotis et al^[@bibr21-2054358120940433]^ (2002)\   1 (25)                                           NR                                                       NR                                                                                           None                                                                                                                    NR                                                           NR
  *Greece*                                                                                                                                                                                                                                                                                                                                                                                                                                              

   Ng et al^[@bibr22-2054358120940433]^ (2000)\             NR                                               1 (33)                                                   NR                                                                                           None                                                                                                                    76.6 (10.2; 70.7 to 88.4)                                    79.6 (25.0; 61.9 to 97.2)
  *United States*                                                                                                                                                                                                                                                                                                                                                                                                                                       

   Singh et al^[@bibr23-2054358120940433]^ (2019)\          NR                                               1 (33)                                                   NR                                                                                           • At least one complication: 2 (33)\                                                                                    NR                                                           NR
  *India*                                                                                                                                                                                                                                                          • Fever: 2 (33)                                                                                                                                                                      

  *Ureteroscopy*---*Case Series*                                                                                                                                                                                                                                                                                                                                                                                                                        

   Baishya et al^[@bibr14-2054358120940433]^ (2012)\        2 (100)                                          0 (0)                                                    NR                                                                                           None                                                                                                                    NR                                                           NR
  *India*                                                                                                                                                                                                                                                                                                                                                                                                                                               

   Franke et al^[@bibr24-2054358120940433]^ (2011)\         9 (100)                                          0 (0)                                                    NR                                                                                           None                                                                                                                    NR                                                           NR
  *Denmark*                                                                                                                                                                                                                                                                                                                                                                                                                                             

   Geavlete et al^[@bibr25-2054358120940433]^ (2017)\       8 (73)                                           Unclear                                                  NR                                                                                           • At least one complication: 3 (27)\                                                                                    NR                                                           NR
  *Romania*                                                                                                                                                                                                                                                        • Fever: 1 (9)\                                                                                                                                                                      
                                                                                                                                                                                                                                                                   • Hematuria: 1 (9)\                                                                                                                                                                  
                                                                                                                                                                                                                                                                   • Renal colic: 1 (9)                                                                                                                                                                 

   Ng et al^[@bibr22-2054358120940433]^ (2000)\             NR                                               0 (0)                                                    NR                                                                                           None                                                                                                                    556.9 (399.6; 274.0 to 839.8)                                300.6 (75.0; 247.5 to 353.6)
  *United States*                                                                                                                                                                                                                                                                                                                                                                                                                                       

   Singh et al^[@bibr23-2054358120940433]^ (2019) *India*   NR                                               0 (0)                                                    NR                                                                                           • At least one complication: 1 (20)\                                                                                    NR                                                           NR
                                                                                                                                                                                                                                                                   • Fever: 1 (20)                                                                                                                                                                      

   Yili et al^[@bibr13-2054358120940433]^ (2012)\           11 (85)                                          2 (15)                                                   None                                                                                         • At least one complication: 3 (23)\                                                                                    NR (NR; 70.7 to 291.7)                                       NR
  *China*                                                                                                                                                                                                                                                          • Low-grade fever: 1 (8)\                                                                                                                                                            
                                                                                                                                                                                                                                                                   • Flank pain: 1 (8)\                                                                                                                                                                 
                                                                                                                                                                                                                                                                   • Moderate stent pain: 1 (8)                                                                                                                                                         

  *Percutaneous Nephrolithotomy---Cohort*                                                                                                                                                                                                                                                                                                                                                                                                               

   Khorrami et al^[@bibr26-2054358120940433]^ (2012)\       ADPKD: 7 (88)\                                   NR                                                       ADPKD: None\                                                                                 • Urinary leakage from nephrostomy tube was longer in patients with ADPKD (31 ± 4 hours) vs. controls (6 ± 1.5 hours)   NR                                                           NR
                                                            CONTROL: 91 (91)                                                                                          CONTROL: None                                                                                                                                                                                                                                                                     

  *Iran* *Percutaneous Nephrolithotomy---Case Series*                                                                                                                                                                                                                                                                                                                                                                                                   

   Al-Kandari et al^[@bibr27-2054358120940433]^ (2009)\     16 (84)                                          3 (16)                                                   Unclear                                                                                      • At least one complication: 3 (15)\                                                                                    150.3 (70.7; NR)                                             132.6 (70.7; NR)
  *Kuwait*                                                                                                                                                                                                                                                         • Mild hematuria with low-grade fever: 1 (5)\                                                                                                                                        
                                                                                                                                                                                                                                                                   • Bleeding through nephrostomy tube after declamping: 1 (5)\                                                                                                                         
                                                                                                                                                                                                                                                                   • Low-grade fever: 1 (5)                                                                                                                                                             

   Al-Kandari et al^[@bibr28-2054358120940433]^ (2008)\     NR                                               2 (7)                                                    • At least one complication: 3 (10)\                                                         None                                                                                                                    NR                                                           NR
  *United States*                                                                                                                                                     • Renal Pelvic Tear: 2 (7)\                                                                                                                                                                                                                                                       
                                                                                                                                                                      • Intraoperative bleeding: 1 (3)                                                                                                                                                                                                                                                  

   Baishya et al^[@bibr14-2054358120940433]^ (2012)\        2 (67)                                           1 (33)                                                   NR                                                                                           • At least one complication: 2 (67)\                                                                                    NR                                                           NR
  *India*                                                                                                                                                                                                                                                          • Postoperative fever: 1 (33)\                                                                                                                                                       
                                                                                                                                                                                                                                                                   • Pain in operating site: 1 (33)                                                                                                                                                     

   Bendigeri et al^[@bibr29-2054358120940433]^ (2016)\      NR                                               3 (23)                                                   NR                                                                                           • At least one complication: Unclear\                                                                                   NR                                                           NR
  *India*                                                                                                                                                                                                                                                          • Fever: 3 (23)\                                                                                                                                                                     
                                                                                                                                                                                                                                                                   • Blood transfusion: 1 (8)                                                                                                                                                           

   Boaz et al^[@bibr30-2054358120940433]^ (2016)\           NR                                               4 (21)                                                   • At least one complication: 1 (5)\                                                          • At least one complication: 4 (21)\                                                                                    179.5 (84.2; 97.2 to 389.0)                                  175.9 (71.6; 97.2 to 309.4)
  *India*                                                                                                                                                             • Blood transfusion: 1 (5)                                                                   • Fever: 4 (21)\                                                                                                                                                                     
                                                                                                                                                                                                                                                                   • Sepsis: 1 (5)                                                                                                                                                                      

   Enganti et al^[@bibr31-2054358120940433]^ (2017)\        NR                                               NR                                                       NR                                                                                           • At least one complication: 5 (23)\                                                                                    NR                                                           NR
  *India*                                                                                                                                                                                                                                                          • Renal pelvic perforation: 1 (5)\                                                                                                                                                   
                                                                                                                                                                                                                                                                   • Hematuria requiring blood transfusion: 2 (9)\                                                                                                                                      
                                                                                                                                                                                                                                                                   • Perirenal fluid collection: 2 (9)                                                                                                                                                  

   Ismayil et al^[@bibr32-2054358120940433]^ (2014)\        2 (67)                                           1 (33)                                                   NR                                                                                           • At least one complication: 3 (100)\                                                                                   NR                                                           NR
  *Azerbaijan*                                                                                                                                                                                                                                                     • Blood transfusion: 3 (100)                                                                                                                                                         

   Khadgi et al^[@bibr33-2054358120940433]^ (2016)\         7 (100)                                          0 (0)                                                    NR                                                                                           • At least one complication: 3 (43)\                                                                                    NR                                                           NR
  *Kuwait*                                                                                                                                                                                                                                                         • Fever: 1 (14)\                                                                                                                                                                     
                                                                                                                                                                                                                                                                   • Urinary tract infection: 1 (14)\                                                                                                                                                   
                                                                                                                                                                                                                                                                   • Bleeding: 1 (14)                                                                                                                                                                   

   Lei et al^[@bibr34-2054358120940433]^ (2014)\            16 (70)                                          6 (26)                                                   NR                                                                                           • At least one complication: Unclear\                                                                                   148.2 (110.1; 77.0 to 568.0)                                 Immediately after: 149.2 (86.2; 72.0 to 475.0)\
  *China*                                                                                                                                                                                                                                                          • Fever: 4 (17)\                                                                                                                                                                     One-month follow-up: 136.2 (86.7; 53.0 to 441.0)4545554444
                                                                                                                                                                                                                                                                   • Urinary tract infection: 3 (13)\                                                                                                                                                   
                                                                                                                                                                                                                                                                   • Blood transfusion: 2 (9)Selective renal artery embolization: 1 (4)                                                                                                                 

   Sabnis et al^[@bibr35-2054358120940433]^ (2016)\         NR                                               0 (0)                                                    NR                                                                                           • At least one complication: 2 (20)\                                                                                    NR                                                           NR
  *United States*                                                                                                                                                                                                                                                  • Fever: 2 (20)                                                                                                                                                                      

   Singh et al^[@bibr36-2054358120940433]^ (2013)\          12 (55)                                          10 (45)                                                  • At least one complication: 4 (18)\                                                         • At least one complication: Unclear\                                                                                   NR                                                           NR
  *India*                                                                                                                                                             • Hypotension requiring resuscitation but did not require termination of procedure: 4 (18)   • Blood transfusion: 9 (32)\                                                                                                                                                         
                                                                                                                                                                                                                                                                   • Fever due to cyst infection: 4 (18)\                                                                                                                                               
                                                                                                                                                                                                                                                                   • Perirenal hematoma collection: 4 (18)\                                                                                                                                             
                                                                                                                                                                                                                                                                   • Renal failure that worsened: 3 (14)\                                                                                                                                               
                                                                                                                                                                                                                                                                   • Hydrothorax: 2 (9)\                                                                                                                                                                
                                                                                                                                                                                                                                                                   • Hemothorax: 1 (5)\                                                                                                                                                                 
                                                                                                                                                                                                                                                                   • Pneumothorax: 1 (5)\                                                                                                                                                               
                                                                                                                                                                                                                                                                   • Paralytic ileus: 3 (14)                                                                                                                                                            

   Singh et al^[@bibr23-2054358120940433]^ (2019)\          NR                                               Unclear                                                  NR                                                                                           • At least one complication: Unclear\                                                                                   NR                                                           NR
  *India*                                                                                                                                                                                                                                                          • Fever: 2 (33)\                                                                                                                                                                     
                                                                                                                                                                                                                                                                   • Urinary tract infection: 1 (17)                                                                                                                                                    

   Srivastava et al^[@bibr37-2054358120940433]^ (2012)\     Unclear                                          3 (14)                                                   NR                                                                                           • At least one complication: Unclear\                                                                                   NR                                                           NR
  *India*                                                                                                                                                                                                                                                          • Fever: 4 (18)\                                                                                                                                                                     
                                                                                                                                                                                                                                                                   • Blood transfusion: 3(14)\                                                                                                                                                          
                                                                                                                                                                                                                                                                   • More than one transfusion: 1 (5)\                                                                                                                                                  
                                                                                                                                                                                                                                                                   • Positive fungal culture with antibiotic treatment for 3 mo: 1 (5)                                                                                                                  

   Umbreit et al^[@bibr38-2054358120940433]^ (2010)\        NR                                               2 (18)                                                   None                                                                                         None                                                                                                                    123.8 (NR; 79.6 to 238.7)                                    123.8 (NR; 70.7 to 247.5)
  *United States*                                                                                                                                                                                                                                                                                                                                                                                                                                       

   Wang et al^[@bibr39-2054358120940433]^ (2017)\           NR                                               7 (64)                                                   NR                                                                                           • At least one complication: Unclear\                                                                                   89.3 (15.9; NR)                                              90.5 (18.6; NR)
  *United States*                                                                                                                                                                                                                                                  • Severe hematuria: 1 (9)\                                                                                                                                                           
                                                                                                                                                                                                                                                                   • Fever: 5 (45)\                                                                                                                                                                     
                                                                                                                                                                                                                                                                   • Paralytic ileus: 1 (9)\                                                                                                                                                            
                                                                                                                                                                                                                                                                   • Urinary tract infection: 3 (27)                                                                                                                                                    

   Zhang et al^[@bibr40-2054358120940433]^ (2014)\          5 (45)                                           4 (36)                                                   NR                                                                                           • At least one complication: Unclear\                                                                                   1337.5 (291.7; 875.2 to 1780.4)                              1262.4 (198.0; 951.2 to 1527.6)
  *China*                                                                                                                                                                                                                                                          • Bleeding: 3 (27)\                                                                                                                                                                  
                                                                                                                                                                                                                                                                   • Fever: 4 (36)\                                                                                                                                                                     
                                                                                                                                                                                                                                                                   • Blood transfusion: 2 (18)\                                                                                                                                                         
                                                                                                                                                                                                                                                                   • Infection: 1 (9)                                                                                                                                                                   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* NR = not reported; ADPKD = autosomal dominant polycystic kidney disease; SD = standard deviations.

Quality Assessment of Studies {#section32-2054358120940433}
-----------------------------

The methods quality score was highly variable and ranged between 4 and 12 out of 22 (where higher scores indicates studies of higher methodological quality).

The ADPKD and outcome definitions affect the internal validity of a study. Only 1 study reported the case definition of ADPKD, which defined ADPKD using the validated, Ravine ultrasonographic criteria.^[@bibr34-2054358120940433],[@bibr41-2054358120940433]^

Definition for stone-free status post-intervention was highly variable across studies. Seven of the 25 studies specified and defined stone-free status as complete clearance or residual fragments less than a prespecified size. The prespecified size for an acceptable residual fragment was less than 4 mm for 5 studies, less than 2 mm for 1 study, and less than 1 mm for 1 study.

The sampling strategy and the source population influenced the generalizability of the findings to the broader ADPKD population who underwent stone intervention. Seven of the 25 studies specified how cases were recruited, and all 7 studies included consecutive or all patients within a specified time frame.^[@bibr13-2054358120940433],[@bibr14-2054358120940433],[@bibr23-2054358120940433],[@bibr27-2054358120940433],[@bibr33-2054358120940433],[@bibr35-2054358120940433],[@bibr38-2054358120940433]^ One study recruited patients from an outpatient setting,^[@bibr21-2054358120940433]^ and 4 studies recruited patients from a hospital setting.^[@bibr18-2054358120940433],[@bibr25-2054358120940433],[@bibr34-2054358120940433],[@bibr40-2054358120940433]^ For the latter, it was unclear whether the cases were recruited from a same day surgery setting, emergency department, inpatient, or an outpatient hospital-based clinic.

One conference proceeding described the efficacy outcomes of PCNL performed in patients with ADPKD compared with non-ADPKD controls, without adjustment for any covariates.^[@bibr26-2054358120940433]^

Shock Wave Lithotripsy {#section33-2054358120940433}
----------------------

We identified 7 case series describing the outcomes and experience of treating stones in patients with ADPKD with SWL (in total, 32 patients).^[@bibr14-2054358120940433],[@bibr18-2054358120940433],[@bibr19-2054358120940433],[@bibr20-2054358120940433],[@bibr21-2054358120940433],[@bibr22-2054358120940433],[@bibr23-2054358120940433]^ The characteristics of SWL for each study are summarized in [Table 3](#table3-2054358120940433){ref-type="table"}.

###### 

Characteristics of Shock Wave Lithotripsy (SWL).

![](10.1177_2054358120940433-table3)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (y)Country (citation)                             Type of lithotripter                    No. of shock waves (mean \[SD; range\])   Voltage of shock wave, kV   Modality used to assess stone-free status           Operative time, minMean (range)
  -------------------------------------------------------- --------------------------------------- ----------------------------------------- --------------------------- --------------------------------------------------- ---------------------------------
  Baishya et al^[@bibr14-2054358120940433]^ (2012)\        Dornier Compact Delta                   \<1500                                    \<13                        X-ray, U/S of the KUB region                        NR
  *India*                                                                                                                                                                                                                    

  Cass^[@bibr19-2054358120940433]^ (1995)\                 Medstone STS Lithotripter               2050 (700; 1000-2400)                     24                          Plain radiograph                                    NR
  *United States*                                                                                                                                                                                                            

  Chen et al^[@bibr20-2054358120940433]^ (1993)\           Dornier HM-3 Lithotripter               2500 (NR; 2000-3000)                      20                          KUB x-ray and excretory urography                   NR
  *Taiwan*                                                                                                                                                                                                                   

  Delakas et al^[@bibr18-2054358120940433]^ (1997)\        Dornier HM-4 Lithotripter               1800 (NR; 1400-2500)                      15-21                       Plain x-ray film and U/S                            NR (35-88)
  *Greece*                                                                                                                                                                                                                   

  Deliveliotis et al^[@bibr21-2054358120940433]^ (2002)\   Dornier HM-4 Lithotripter               Unclear                                   23                          Plain KUB x-ray film and U/S                        NR
  *Greece*                                                                                                                                                                                                                   

  Ng et al^[@bibr22-2054358120940433]^ (2000)\             Dornier HM-3 or MFL 5000 Lithotripter   4333 (3402; 1800-8200)                    NR                          Plain x-ray film and kidney U/S or noncontrast CT   NR
  *United States*                                                                                                                                                                                                            

  Singh et al^[@bibr23-2054358120940433]^ (2019)\          NR                                      \<1500                                    \<13                        U/S or KUB x-ray                                    100 (80-120)
  *India*                                                                                                                                                                                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* SD = standard deviation; kV = kilovolts; U/S = ultrasound; KUB = kidney, ureter, bladder; NR = not reported; CT = computed tomography.

None to 69% of the patients were stone free after a single SWL session, and 15% to 67% of the patients received additional follow-up procedures to achieve stone-free status.^[@bibr14-2054358120940433],[@bibr18-2054358120940433],[@bibr19-2054358120940433],[@bibr20-2054358120940433],[@bibr21-2054358120940433],[@bibr22-2054358120940433],[@bibr23-2054358120940433]^ In 4 of the 6 case series that examined at least one postoperative SWL complication, no patients experienced any complications postoperatively.^[@bibr21-2054358120940433],[@bibr19-2054358120940433],[@bibr20-2054358120940433],[@bibr22-2054358120940433]^ The percentage of patients that experienced at least one complication was unclear in 1 study,^[@bibr18-2054358120940433]^ and 33% of the patients described by Singh et al^[@bibr23-2054358120940433]^ experienced fever postoperatively. The reported postoperative complications of SWL in patients with ADPKD included colic pain and fever.^[@bibr18-2054358120940433],[@bibr23-2054358120940433]^ Delakas and colleagues^[@bibr18-2054358120940433]^ specified that none of the patients experienced any intraoperative complications, whereas the remaining 6 case series did not report any intraoperative complications.^[@bibr14-2054358120940433],[@bibr19-2054358120940433],[@bibr20-2054358120940433],[@bibr21-2054358120940433],[@bibr22-2054358120940433],[@bibr23-2054358120940433]^

Ureteroscopy {#section34-2054358120940433}
------------

We identified 6 case series reporting stone treatment in patients with ADPKD using ureteroscopy (in total, 42 patients).^[@bibr13-2054358120940433],[@bibr14-2054358120940433],[@bibr22-2054358120940433],[@bibr23-2054358120940433],[@bibr24-2054358120940433],[@bibr25-2054358120940433]^ The characteristics of ureteroscopy are detailed in [Table 4](#table4-2054358120940433){ref-type="table"}.

###### 

Characteristics of Ureteroscopy.

![](10.1177_2054358120940433-table4)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (y)*Country* (citation)                       Type of ureteroscope                   Instrument used to fragment stones                                                                                                                 Modality used to assess stone-free status          Operative time, min\
                                                                                                                                                                                                                                                                                                    Mean (range)
  ---------------------------------------------------- -------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------- ----------------------
  Baishya et al^[@bibr14-2054358120940433]^ (2012)\    NR                                     NR                                                                                                                                                 X-ray, U/S of the KUB region at 1 mo               NR
  *India*                                                                                                                                                                                                                                                                                           

  Franke et al^[@bibr24-2054358120940433]^ (2011)\     Flexible ureteroscope                  NR                                                                                                                                                 CT                                                 NR
  *Denmark*                                                                                                                                                                                                                                                                                         

  Geavlete et al^[@bibr25-2054358120940433]^ (2017)\   Flexible ureteroscope                  Laser lithotripsy                                                                                                                                  NR                                                 NR
  *Romania*                                                                                                                                                                                                                                                                                         

  Ng et al^[@bibr22-2054358120940433]^ (2000)\         NR                                     Laser for 1 of 2 patients                                                                                                                          Plain x-ray film and renal U/S or noncontrast CT   NR
  *United States*                                                                                                                                                                                                                                                                                   

  Singh et al^[@bibr23-2054358120940433]^ (2019)\      Semi-rigid and flexible ureteroscope   Holium YAG laser                                                                                                                                   Plain x-ray KUB and U/S KUB                        60 (30- 90)
  *India*                                                                                                                                                                                                                                                                                           

  Yili et al^[@bibr13-2054358120940433]^ (2012)\       7.2 flexible ureteroscope              Holium YAG laser lithotripsy performed via 200 μm (Dornier Lightguide Super 200) core-sized fiber until only very small pieces (\<1 mm) remained   U/S                                                46 (36-60)
  *China*                                                                                                                                                                                                                                                                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* NR = not reported; U/S = ultrasound; KUB = kidney, ureter, bladder; CT = computed tomography.

After a single session, 73% to 100% of the patients were stone free.^[@bibr13-2054358120940433],[@bibr24-2054358120940433],[@bibr25-2054358120940433]^ In 4 case series, no patients required a second procedure to facilitate complete stone removal,^[@bibr14-2054358120940433],[@bibr22-2054358120940433],[@bibr23-2054358120940433],[@bibr24-2054358120940433]^ whereas another case series reported 15% undergoing a second ureteroscopy 1 week following the first procedure.^[@bibr13-2054358120940433]^ The percentage of patients that underwent a second procedure was unclear or not reported in 1 case series.^[@bibr25-2054358120940433]^ Three case series reported that none of the patients experienced any postoperative complications.^[@bibr14-2054358120940433],[@bibr22-2054358120940433],[@bibr24-2054358120940433]^ About 20% to 27% of the patients experienced at least one postoperative complication, such as fever, hematuria, and pain in the remaining 3 case series.^[@bibr13-2054358120940433],[@bibr23-2054358120940433],[@bibr25-2054358120940433]^ One case series reported that not a single patient experienced any intraoperative outcomes during ureteroscopy,^[@bibr13-2054358120940433]^ whereas the remaining 5 case series did not report about any intraoperative outcomes.^[@bibr14-2054358120940433],[@bibr22-2054358120940433],[@bibr23-2054358120940433],[@bibr24-2054358120940433],[@bibr25-2054358120940433]^

Percutaneous Nephrolithotomy {#section35-2054358120940433}
----------------------------

Sixteen case series ^[@bibr14-2054358120940433],[@bibr23-2054358120940433],[@bibr27-2054358120940433],[@bibr28-2054358120940433][@bibr29-2054358120940433][@bibr30-2054358120940433][@bibr31-2054358120940433][@bibr32-2054358120940433][@bibr33-2054358120940433][@bibr34-2054358120940433][@bibr35-2054358120940433][@bibr36-2054358120940433][@bibr37-2054358120940433][@bibr38-2054358120940433][@bibr39-2054358120940433]-[@bibr40-2054358120940433]^ and 1 cohort study^[@bibr26-2054358120940433]^ reported the use of PCNL for stone removal in adults with ADPKD, with 3 to 29 patients per series (3 to 30 kidneys) (in total, 237 patients). Percutaneous nephrolithotomy--specific characteristics of each study are detailed in [Table 5](#table5-2054358120940433){ref-type="table"}.

###### 

Characteristics of Percutaneous Nephrolithotomy (PCNL).

![](10.1177_2054358120940433-table5)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (y)*Country* (citation)                         \% of affected kidneys with multiple access tract   Modality used to guide procedure   Dilator                                                                                               Type of nephroscope                                                  Instrument used to fragment stones                                                                                        Instrument used to remove stones                                                   Modality used to assess stone-free status                                                                                                                       Operative time, minMean (range)
  ------------------------------------------------------ --------------------------------------------------- ---------------------------------- ----------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  Khorrami et al^[@bibr26-2054358120940433]^ (2012)\     NR                                                  Fluoroscopy                        Metal telescoping dilator                                                                             NR                                                                   NR                                                                                                                        NR                                                                                 NR                                                                                                                                                              NR
  *Iran*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Al-Kandari et al^[@bibr27-2054358120940433]^ (2009)\   5                                                   Fluoroscopy                        Amplatz sequential facial dilator in 14 procedures and Nephromax balloons in remaining 6 procedures   26F rigid nephroscope                                                U/S and/or pneumatic disintegration were used together                                                                    NR                                                                                 • Day of procedure: plain abdominal x-ray and intraoperative nephrostography\                                                                                   NR
  *Kuwait*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              • At time of nephrostomy tube removal (2-4 d postoperatively): plain abdominal x-ray for radiopaque stone; nephrostomy or nonspiral CT for radiolucent stones   

  Al-Kandari et al^[@bibr28-2054358120940433]^ (2008)\   NR                                                  NR                                 NR                                                                                                    NR                                                                   NR                                                                                                                        NR                                                                                 NR                                                                                                                                                              NR
  *United States*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Baishya et al^[@bibr14-2054358120940433]^ (2012)\      NR                                                  • U/S (67%)\                       NR                                                                                                    NR                                                                   NR                                                                                                                        NR                                                                                 X-ray, ultrasonography of the KUB region at 1 mo                                                                                                                Unclear
  *India*                                                                                                    • Fluoroscopy (33%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Bendigeri et al^[@bibr29-2054358120940433]^ (2016)\    NR                                                  NR                                 NR                                                                                                    NR                                                                   NR                                                                                                                        NR                                                                                 NR                                                                                                                                                              NR
  *India*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Boaz et al^[@bibr30-2054358120940433]^ (2016)\         NR                                                  NR                                 NR                                                                                                    NR                                                                   NR                                                                                                                        NR                                                                                 NR                                                                                                                                                              85
  *India*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Enganti et al^[@bibr31-2054358120940433]^ (2017)\      NR                                                  NR                                 NR                                                                                                    NR                                                                   NR                                                                                                                        NR                                                                                 NR                                                                                                                                                              NR
  *India*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Ismayil et al^[@bibr32-2054358120940433]^ (2014)\      NR                                                  NR                                 NR                                                                                                    NR                                                                   NR                                                                                                                        NR                                                                                 CT                                                                                                                                                              NR
  *Azerbaijan*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Khadgi et al^[@bibr33-2054358120940433]^ (2016)\       0                                                   Fluoroscopy                        Fascial dilator                                                                                       Semi-rigid ureteroscope (8.5/11.5F)                                  1.5-mm pneumatic lithotripsy probe                                                                                        A pulsatile pressurized irrigation pump; occasionally cleared by forceps           • 1-d postoperatively: KUB and U/S\                                                                                                                             54.9 (45-60)
  *Kuwait*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              • 12-wk postoperatively: noncontrast CT                                                                                                                         

  Lei et al^[@bibr34-2054358120940433]^ (2014)\          13                                                  • Fluoroscopy (91%)\               Fascial dilator                                                                                       8/9.8F semi-rigid ureteroscope                                       Pneumatic lithotripsy or holmium laser                                                                                    Forceps and small fragments flushed out with an endoscopic pulsed perfusion pump   Plain KUB radiography, U/S, and CT                                                                                                                              95.2 (NR)
  *China*                                                                                                    • U/S (9%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Sabnis et al^[@bibr35-2054358120940433]^ (2016)\       NR                                                  U/S or fluoroscopy                 NR                                                                                                    NR                                                                   NR                                                                                                                        NR                                                                                 NR                                                                                                                                                              NR
  *United States*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Singh et al^[@bibr36-2054358120940433]^ (2013)\        31                                                  Fluoroscopy                        Alkene metallic dilator up to 26F/28F                                                                 26F (Richard Wolf) nephroscope                                       Pneumatic lithoclast (Swiss Lithoclast)                                                                                   NR                                                                                 X-ray KUB and renal U/S                                                                                                                                         90 (70-120)
  *India*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Singh et al^[@bibr23-2054358120940433]^ (2019)\        NR                                                  U/S and fluoroscopy                Serial dilator                                                                                        Unclear                                                              laser or pneumatic lithoclast                                                                                             NR                                                                                 Plain x-ray KUB and U/S KUB                                                                                                                                     112 (70-145)
  *India*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Srivastava et al^[@bibr37-2054358120940433]^ (2012)\   Unclear                                             NR                                 Amplatz sequential facial dilators                                                                    28F nephroscope; flexible nephroscope in some cases                  Pneumatic lithotripter; holmium laser with flexible nephroscope in 3 patients where forceps extraction was not possible   Forceps                                                                            Noncontrast CT                                                                                                                                                  NR
  *India*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Umbreit et al^[@bibr38-2054358120940433]^ (2010)\      45                                                  Fluoroscopy                        Amplatz fascial dilators                                                                              Rigid nephroscope; 2 patients also required a flexible nephroscope   • Ultrasonic lithotripsy: 10 (91%)\                                                                                       • Basket: 2 (9%)                                                                   • Immediately after: endoscopy nephrostogram\                                                                                                                   • Unilateral PCNL = 66 (47-82)\
  *United States*                                                                                                                                                                                                                                                                                                          • Electrohydraulic lithotripsy: 2 (9%)                                                                                                                                                                       • One day after: Antegrade nephrostogram                                                                                                                        • Bilateral PCNL = 127 (121-132)

  Wang et al^[@bibr39-2054358120940433]^ (2017)\         18                                                  U/S                                Amplatz fascial dilators                                                                              Rigid                                                                Pneumatic and U/S disintegration                                                                                          NR                                                                                 NR                                                                                                                                                              NR
  United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Zhang et al^[@bibr40-2054358120940433]^ (2014)\        NR                                                  U/S                                6F plastic dilator then metal coaxial metal dilators (second step)                                    Rigid nephroscope                                                    U/S and pneumatic disintegration                                                                                          Graspers                                                                           Ultrasound/ KUB film                                                                                                                                            77 (45-128)
  *China*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* NR = not reported; U/S = ultrasound; CT = computed tomography; KUB = kidney, ureter, bladder; PCNL = percutaneous nephrolithotomy.

The stone-free status of patients after a single session ranged from 45% to 100%, and 0% to 64% of the patients required a follow-up procedure for residual stones among the 12 studies that reported it.^[@bibr14-2054358120940433],[@bibr27-2054358120940433],[@bibr28-2054358120940433][@bibr29-2054358120940433]-[@bibr30-2054358120940433],[@bibr32-2054358120940433][@bibr33-2054358120940433][@bibr34-2054358120940433][@bibr35-2054358120940433][@bibr36-2054358120940433][@bibr37-2054358120940433][@bibr38-2054358120940433][@bibr39-2054358120940433]-[@bibr40-2054358120940433]^ Two studies reported no patients experienced any postoperative complications,^[@bibr38-2054358120940433],[@bibr28-2054358120940433]^ 7 case series did not report the percentage of patients with complications,^[@bibr23-2054358120940433],[@bibr29-2054358120940433],[@bibr34-2054358120940433],[@bibr36-2054358120940433],[@bibr37-2054358120940433],[@bibr39-2054358120940433],[@bibr40-2054358120940433]^ and 15% to 100% of patients experienced at least one complication among the remaining 7 case series.^[@bibr14-2054358120940433],[@bibr23-2054358120940433],[@bibr27-2054358120940433],[@bibr30-2054358120940433][@bibr31-2054358120940433][@bibr32-2054358120940433]-[@bibr33-2054358120940433]^ The postoperative complications of PCNL included fever, pain, hematuria, bleeding, urinary tract infection, cyst infection, perirenal hematoma collection, hydrothorax, hemothorax, pneumothorax, paralytic ileus, worsening of preexisting renal failure, blood transfusion, renal pelvic perforation, urinary leakage from nephrostomy tube, and sepsis.^[@bibr14-2054358120940433],[@bibr23-2054358120940433],[@bibr27-2054358120940433],[@bibr29-2054358120940433][@bibr30-2054358120940433][@bibr31-2054358120940433][@bibr32-2054358120940433][@bibr33-2054358120940433][@bibr34-2054358120940433][@bibr35-2054358120940433][@bibr36-2054358120940433]-[@bibr37-2054358120940433],[@bibr39-2054358120940433],[@bibr40-2054358120940433]^ None of the patients described by Umbreit et al^[@bibr38-2054358120940433]^ experienced any intraoperative complications. In 3 other case series, at least one patient experienced an intraoperative complication, including bleeding, renal pelvic tear, and hypotension^[@bibr28-2054358120940433],[@bibr30-2054358120940433],[@bibr36-2054358120940433]^; the remaining studies did not clearly report any intraoperative complications.^[@bibr14-2054358120940433],[@bibr23-2054358120940433],[@bibr27-2054358120940433],[@bibr29-2054358120940433],[@bibr31-2054358120940433][@bibr32-2054358120940433][@bibr33-2054358120940433][@bibr34-2054358120940433]-[@bibr35-2054358120940433],[@bibr37-2054358120940433],[@bibr39-2054358120940433],[@bibr40-2054358120940433]^

Khorrami et al^[@bibr26-2054358120940433]^ conducted a cohort study of patients undergoing PCNL, comparing 8 patients with ADPKD to 100 patients without ADPKD. There were no significant between-group differences in stone-free status, the rise in the concentration of serum creatinine after the procedure, or the decline in concentration of hemoglobin after the procedure.^[@bibr26-2054358120940433]^ However, urinary leakage lasted significantly longer in patients with ADPKD compared with patients without ADPKD.^[@bibr26-2054358120940433]^

Discussion {#section36-2054358120940433}
==========

We conducted a systematic review of 25 studies describing at least one postoperative outcome of SWL, ureteroscopy, and PCNL in patients with ADPKD to summarize the literature and to identify knowledge gaps. The estimates are limited by small sample sizes and between-study variability in patient characteristics, stone characteristics, and treatment protocol. This concern notwithstanding, based on the literature published to date, the percentage of patients who were stone free after 1 session ranged from none to 69% for SWL, 73% to 100% for ureteroscopy, and 45% to 100% for PCNL. The overall complication rate ranged from none to 33% for SWL, none to 27% for ureteroscopy, and none to 100% for PCNL. Postoperative complications experienced by patients with ADPKD after any intervention included residual stones, pain, and fever. Postoperative hematuria was observed after ureteroscopy and PCNL. Other PCNL complications included urinary leakage, bleeding, renal pelvic perforation, perirenal fluid collection, urinary tract infection, cyst infection, worsening renal failure, hydrothorax, hemothorax, pneumothorax, and paralytic ileus.

The postoperative complication and stone-free rates of all 3 stone interventions were highly variable. The variability in postoperative complication and stone-free rates can be explained by between-study variability in the definitions used for stone-free status, sample size, treatment protocol, timing when imaging was performed postintervention, and the type of imaging performed to assess stone-free status postintervention. For example, among all imaging modalities used to assess stone-free status, computed tomography (CT) is the most sensitive modality to detect residual stones.^[@bibr42-2054358120940433],[@bibr43-2054358120940433]^ Ultrasound and kidney, ureter, and bladder (KUB) radiograph cannot detect radiolucent stones, such as uric acid stones, and the ultrasound performance is poor for patients who are obese and patients with residual fragments less than 5 mm^[@bibr42-2054358120940433],[@bibr43-2054358120940433]^ and would be expected to be less sensitive in the setting of ADPKD. As a result, studies that use CT postoperatively would report a lower stone-free rate compared with studies that use ultrasound or KUB. Patient and stone characteristics, including ADPKD-specific characteristics such as residual renal function and cyst volume and location, influence intervention choice and subsequent success and complication rates. In general, symptomatic stones that are between 1 and 2 cm would be treated with either SWL or ureteroscopy, and PCNL would be reserved for stones greater than 2 cm, or in patients where retrograde access is not possible. The success rate of all 3 interventions is dependent on gaining optimal access to stones.^[@bibr44-2054358120940433]^ Therefore, variability in patient and stone characteristics across studies also explain the variability in reported success and complication rate.

It is difficult to determine whether SWL, ureteroscopy, and PCNL are truly efficacious and safe in patients with ADPKD because the variability described above also limits indirect comparison of stone interventions success and complication rates between that reported in patients with ADPKD and the general population. Furthermore, the ADPKD cases described in the studies were likely more selected than the general population because of their complex kidney anatomy. Future randomized controlled trials or observational studies that use a representative sample of patients with ADPKD and address potential confounding factors are required to elucidate whether ADPKD is truly associated with poor outcomes following SWL, ureteroscopy, and PCNL.

Our findings must be interpreted with caution due to several limitations. First, except for 1 cohort study, all studies were clinical case series. Although case series give some insight into the outcomes of stone interventions and are useful for generating new hypotheses, the observations are not necessarily generalizable to the broader ADPKD population. Based on our systematic, comprehensive search, the conference proceeding published by Khorrami et al (2012) is the only cohort study in the literature.^[@bibr36-2054358120940433]^ Although they compared the outcomes of PCNL in patients with ADPKD to patients without ADPKD, they did not adjust for any covariates. Second, the sample size of all included studies, including the cohort study, was small so the reported estimates were imprecise. Third, most of the data were retrospectively collected. As a result, the conclusions were highly dependent on the accuracy of medical records. The retrospective and unsystematic approach to data collection may also have introduced attrition bias.^[@bibr45-2054358120940433]^ Attrition bias is when patient's prognosis affects their follow-up; patients with a less favorable outcome will more likely return for follow-up visits. As a result, the interventions may misleadingly appear less safe and efficacious in this group of patients. Fourth, the inclusion and exclusion criteria were not explicitly reported in all identified studies. Finally, all studies published to date did not describe the cystic volume in patients with ADPKD. As a result, it was difficult to elucidate whether and how cystic volume influences postoperative complication and success rates.

Aside from inherent limitations of the information in the primary studies, with respect to the quality of this review, we used a very comprehensive search strategy to identify relevant literature. Data were carefully abstracted using a robust form. Our study is the first systematic review to summarize the outcomes of stone interventions in adults with ADKPD.

Conclusions {#section37-2054358120940433}
===========

Our systematic review shows that empirical evidence on the efficacy and safety of SWL, ureteroscopy, and PCNL in ADPKD is limited. Our findings corroborate Mallett et al's suggestion to undertake methodologically rigorous studies to understand the consequences of these procedures in patients with ADPKD.^[@bibr8-2054358120940433]^
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